Tryg’s Supervisory Board has today approved the interim report for Q2 2026. Tryg reported an insurance service result of DKK 1,190m (DKK 2,307m) and a combined ratio of 88.8% (77.2%) in Q2 2026. The insurance service result was DKK 2,390m (up approx. 4% y/y) equal to a combined ratio of 77.4% when excluding the one-off provision related to the Supreme Court ruling on Danish workers’ compensation from 28 April 2026, which was recognised fully in the Q2 accounts. The insurance service result was supported by an underlying claims ratio improvement of 50 basis points, up from 40 basis points in Q1 2026, including strong performance in Norway and a premium growth of 3.3% (4.0%) in local currencies. The investment result was DKK 262m (DKK 110m), showcasing the strength of Tryg’s low-risk investment approach in volatile markets. Pre-tax...

Tryg Forsikring A/S has published its half-year report 2026. Download the report at www.tryg.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentTryg Forsikring AS – Half year report 2026

In connection with the resolution of the General Meeting of AS Ekspress Grupp held on 1 June 2026 to terminate the trading with the shares of Ekspress Grupp on the Baltic main list of Nasdaq Tallinn Stock Exchange, the Management Board of Ekspress Grupp has decided to stop publishing information about Group’s digital subscriptions. Ekspress Grupp’s business operations will continue as usual. Rain SarapuuCFO of the Grouprain.sarapuu@egrupp.ee   AS Ekspress Grupp is the leading Baltic media group whose key activities include web media content production, and publishing of newspapers, magazines and books. The Group also operates an electronic ticket sales platform and ticket sales offices in Latvia and Estonia, offers digital outdoor screen service in Estonia and Latvia. In addition, the Group companies organize conferences, trainings and...

On 1 June 2026, EfTEN Real Estate Fund AS acquired a 100% holding in Magistral Kaubanduskeskus OÜ. The purchase price was based on an investment property valued at €31,690 thousand, and the fund expects a net yield of 8.1% on the investment. In June, the Magistrali shopping centre earned rental income of €213 thousand. At the end of June the centre had 165.5 m² of vacant lettable space, for which a lease has now been signed, meaning the centre is now fully let. In June 2026, EfTEN Real Estate Fund AS earned consolidated rental income of €2,897 thousand, €229 thousand more than in May. The acquisition of the Magistrali shopping centre accounted for the majority of this increase, but rental income also rose owing to new leases signed in the Pärnu mnt 102, Ulonu and Evolution office buildings. The fund’s office vacancy decreased to...

As of 31 July 2026, Aivar Tihane will not continue as a member of the Management Board of Akciju sabiedrba “Gaso, a subsidiary of AS Elenger Grupp. The Management Board of Akciju sabiedrba “Gaso” will then continue with three members. Additional information:Kadri LaanveeInvestor Relations ManagerPhone: +372 5156662e-mail: kadri.laanvee@infortar.eewww.infortar.ee/en/investor

Liven AS group’s (Liven) wholly owned subsidiary Liven Kodu 25 OÜ has entered into a notarised agreement to acquire development properties located at Pärnu maantee 35, 37 and 41 in Tallinn city centre. The monetary value of the transaction is EUR 10 million, while the estimated total investment volume of the project is approximately EUR 40 million. Under the notarised sale agreement, ownership of the properties will transfer to Liven upon the conclusion of a real right agreement, which is planned to be concluded within two months at the latest. Three buildings of 3–7 storeys are planned on the properties, with a total above-ground building right of 15,000 m², of which approximately 80% will be residential premises and 20% commercial premises; the commercial premises intended for public use will be located on the ground floors of the buildings...

HONG KONG, July 09, 2026 (GLOBE NEWSWIRE) — On July 7, 2026, CICC successfully held the 4th China–Southeast Asia Economic and Finance Forum in Singapore. Under the theme of “Redefining Capital Flows and Supply Chain Synergy,” the forum brought together over 200 government officials, institutional investors, business leaders, and CICC representatives from across the region to discuss China and Southeast Asia’s macroeconomic outlook, investment opportunities, cross-border capital flows, and supply chain collaboration. In the opening speech, Liang Dongqing, Member of CICC’s Management Committee, Secretary to the Board of Directors, and President of CICC International, highlighted China’s economic resilience and noted that artificial intelligence, innovative pharmaceuticals and advanced manufacturing are becoming new engines of growth....

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 87,500 shares of common stock at a price per pre-funded warrant of $33.209, for gross proceeds of approximately $50.0 million. The private placement is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise...

Continued Growth Underpins First Full Year Net Revenue of US$115M NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu. Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major U.S. pediatric centers. Our capital position is strong, operational activities are well funded through revenue growth, and the new five-year...